Breast cancer drug Truqap, manufacturer AstraZeneca, failed main goal in CAPItello-290 trial for metastatic triple-negative breast cancer. Breast cancer drug Truqap, manufacturer AstraZeneca, failed main goal in CAPItello-290 trial for metastatic triple-negative breast cancer. Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle
November 20, 2024
- Deep learning architecture enables higher efficiency in light microscopy image improvement
- Bioeconomy in Colombia: DNA analysis shows a vital shellfish in decline
- Five Ways R.F.K. Jr. Could Undermine Lifesaving Childhood Vaccines
- Why Ghanaian farmers have been unable to capitalize on record cocoa prices
Headlines
